309 related articles for article (PubMed ID: 27917702)
21. Treatment and Prognosis of Newly Diagnosed Advanced-Stage Extranodal Natural Killer/T-Cell Lymphoma: A Single-Center Real-World Study across Two Decades.
Wei YC; Qi F; Chen B; Zhang CG; Fang H; Zhang D; Qi SN; Chai Y; Li YX; Dong M
Chemotherapy; 2024; 69(2):108-121. PubMed ID: 37984344
[TBL] [Abstract][Full Text] [Related]
22. Differential clinical significance of pre-, interim-, and post-treatment plasma Epstein-Barr virus DNA load in NK/T-cell lymphoma treated with P-GEMOX protocol.
Wang XX; Li PF; Bai B; Gao Y; Rong QX; Cai QQ; Lin SX; Zhang YJ; Li ZM; Jiang WQ; Huang HQ
Leuk Lymphoma; 2019 Aug; 60(8):1917-1925. PubMed ID: 30646796
[TBL] [Abstract][Full Text] [Related]
23. Promising clinical outcomes of sequential and "Sandwich" chemotherapy and extended involved-field intensity-modulated radiotherapy in patients with stage I
Wang HY; Niu SQ; Yang YY; Li YY; Chen HB; Zhang YJ
Cancer Med; 2018 Dec; 7(12):5863-5869. PubMed ID: 30484966
[TBL] [Abstract][Full Text] [Related]
24. The DDGP (cisplatin, dexamethasone, gemcitabine, and pegaspargase) regimen for treatment of extranodal natural killer (NK)/T-cell lymphoma, nasal type.
Zhang L; Li S; Jia S; Nan F; Li Z; Cao J; Fan S; Zhang C; Su L; Wang J; Xue H; Zhang M
Oncotarget; 2016 Sep; 7(36):58396-58404. PubMed ID: 27517317
[TBL] [Abstract][Full Text] [Related]
25. Radiotherapy followed by DICEP regimen in treatment of newly diagnosed, stage IE/IIE, extranodal NK/T-cell lymphoma patients.
Liu Y; Xue K; Xia Z; Jin J; Wang J; Sun H; Lv F; Liu X; Cao J; Hong X; Guo Y; Ma X; Zhang Q
Cancer Med; 2020 Aug; 9(15):5400-5405. PubMed ID: 32519518
[TBL] [Abstract][Full Text] [Related]
26. Intensity-modulated radiation therapy followed by GDP chemotherapy for newly diagnosed stage I/II extranodal natural killer/T cell lymphoma, nasal type.
Huang Y; Yang J; Liu P; Zhou S; Gui L; He X; Qin Y; Zhang C; Yang S; Xing P; Sun Y; Shi Y
Ann Hematol; 2017 Sep; 96(9):1477-1483. PubMed ID: 28695246
[TBL] [Abstract][Full Text] [Related]
27. Effectiveness of gemcitabine, pegaspargase, cisplatin, and dexamethasone (DDGP) combination chemotherapy in the treatment of relapsed/refractory extranodal NK/T cell lymphoma: a retrospective study of 17 patients.
Zhou Z; Li X; Chen C; Li X; Zhang L; Li L; Wang X; Ma W; Fu X; Wu J; Sun Z; Zhang X; Li Z; Yan J; Chang Y; Lu L; Qin B; Li X; Wen J; Zhang M
Ann Hematol; 2014 Nov; 93(11):1889-94. PubMed ID: 24923454
[TBL] [Abstract][Full Text] [Related]
28. Short-Course Versus Long-Course Chemoradiotherapy for Stage IE-IIE Extranodal Natural Killer/T cell Lymphoma, Nasal Type: A Multicenter Retrospective Study.
Li J; Li Y; Zhong M; Liu X; Song Y; Li J; Li K; Yi P
Med Sci Monit; 2018 May; 24():2683-2692. PubMed ID: 29712887
[TBL] [Abstract][Full Text] [Related]
29. Sequential DICE combined with l-asparaginase chemotherapy followed by involved field radiation in newly diagnosed, stage IE to IIE, nasal and extranodal NK/T-cell lymphoma.
Dong LH; Zhang LJ; Wang WJ; Lei W; Sun X; Du JW; Gao X; Li GP; Li YF
Leuk Lymphoma; 2016 Jul; 57(7):1600-6. PubMed ID: 26726970
[TBL] [Abstract][Full Text] [Related]
30. A phase 2 study of methotrexate, etoposide, dexamethasone, and pegaspargase chemotherapy for newly diagnosed, relapsed, or refractory extranodal natural killer/T-cell lymphoma, nasal type: a multicenter trial in Northwest China.
Liang R; Gao GX; Chen JP; Wang JS; Wang XM; Zeng Y; Bai QX; Zhang T; Yang L; Dong BX; Gu HT; Shu MM; Hao CX; Wang JH; Zhang N; Chen XQ
Hematol Oncol; 2017 Dec; 35(4):619-629. PubMed ID: 27723108
[TBL] [Abstract][Full Text] [Related]
31. SVILE regimen, a combination of dexamethasone, vindesine, ifosfamide, pegaspargase, and etoposide, for treating relapsed/refractory extranodal natural killer/T-cell lymphoma, nasal type.
Wei L; Wang L; Cong J; Yang L; Ye J; Li X; Yao N; Yang J; Wang J
Leuk Res; 2020 Sep; 96():106422. PubMed ID: 32721642
[TBL] [Abstract][Full Text] [Related]
32. Ki-67 Can Predict the Response to the Gemcitabine, Oxaliplatin And L-asparaginase Regimen (GELOX) and Prognosis in Patients with Nasal Natural Killer/T-cell Lymphoma.
Zhang J; Jiang W; Wang WD; Liu CC; Hu YP; Xia ZJ
Asian Pac J Cancer Prev; 2015; 16(11):4515-20. PubMed ID: 26107196
[TBL] [Abstract][Full Text] [Related]
33. Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma study.
Kim SJ; Kim K; Kim BS; Kim CY; Suh C; Huh J; Lee SW; Kim JS; Cho J; Lee GW; Kang KM; Eom HS; Pyo HR; Ahn YC; Ko YH; Kim WS
J Clin Oncol; 2009 Dec; 27(35):6027-32. PubMed ID: 19884539
[TBL] [Abstract][Full Text] [Related]
34. Combination of anti-PD-1 antibody with P-GEMOX as a potentially effective immunochemotherapy for advanced natural killer/T cell lymphoma.
Cai J; Liu P; Huang H; Li Y; Ma S; Zhou H; Tian X; Zhang Y; Gao Y; Xia Y; Zhang X; Yang H; Li L; Cai Q
Signal Transduct Target Ther; 2020 Dec; 5(1):289. PubMed ID: 33376237
[TBL] [Abstract][Full Text] [Related]
35. Radiotherapy vs sequential pegaspargase, gemcitabine, cisplatin and dexamethasone and radiotherapy in newly diagnosed early natural killer/T-cell lymphoma: A randomized, controlled, open-label, multicenter study.
Zhang L; Wang Y; Li X; Li L; Wang X; Sun Z; Wu J; Fu X; Zhang X; Yu H; Wang G; Chang Y; Yan J; Zhou Z; Wu X; Nan F; Li W; Zhang M
Int J Cancer; 2021 Mar; 148(6):1470-1477. PubMed ID: 33034052
[TBL] [Abstract][Full Text] [Related]
36. Combined chemoradiation for the management of nasal natural killer (NK)/T-cell lymphoma: elucidating the significance of systemic chemotherapy.
Guo Y; Lu JJ; Ma X; Wang B; Hong X; Li X; Li J
Oral Oncol; 2008 Jan; 44(1):23-30. PubMed ID: 17306611
[TBL] [Abstract][Full Text] [Related]
37. PEG-L-CHOP treatment is safe and effective in adult extranodal NK/T-cell lymphoma with a low rate of clinical hypersensitivity.
Zheng W; Gao Y; Ke X; Zhang W; Su L; Ren H; Lin N; Xie Y; Tu M; Liu W; Ping L; Ying Z; Zhang C; Deng L; Wang X; Song Y; Zhu J
BMC Cancer; 2018 Sep; 18(1):910. PubMed ID: 30241515
[TBL] [Abstract][Full Text] [Related]
38. DDGP versus SMILE in Newly Diagnosed Advanced Natural Killer/T-Cell Lymphoma: A Randomized Controlled, Multicenter, Open-label Study in China.
Li X; Cui Y; Sun Z; Zhang L; Li L; Wang X; Wu J; Fu X; Ma W; Zhang X; Chang Y; Nan F; Li W; Su L; Wang J; Xue H; Zhang M
Clin Cancer Res; 2016 Nov; 22(21):5223-5228. PubMed ID: 27060152
[TBL] [Abstract][Full Text] [Related]
39. "Sandwich" Chemotherapy (CT) with Radiotherapy (RT) improves outcomes in patients with stage IE/IIE extranodal natural killer (NK)/T-cell Lymphomas.
Zhang J; Zhu MY; Wang L; Wang H; Wang WD; Geng QR; Lu Y
Asian Pac J Cancer Prev; 2013; 14(7):4061-6. PubMed ID: 23991953
[TBL] [Abstract][Full Text] [Related]
40. [Analysis of prognostic factors of extranodal NK/T-cell lymphoma treated with pegaspargase/L-asparaginase: a multicenter retrospective study].
Shen ZY; Chen XC; Shan HR; Jia T; Gu WY; Wang F; Teng QL; Wang L; Wang CL; Shi YY; Zhang H; Miao YQ; Zhu TG; Ji CY; Ye JJ; Zhang MZ; Zhang XD; Wang L; Xu KL; Sang W
Zhonghua Xue Ye Xue Za Zhi; 2023 Aug; 44(8):642-648. PubMed ID: 37803837
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
